Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 4Phase 1/2 2Phase 1 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 3Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1

Interventions

Carboplatin 129pembrolizumab 124Cisplatin 114Paclitaxel 102Gemcitabine 85Specimen Handling 80Magnetic Resonance Spectroscopy 80Docetaxel 70Dexamethasone 59Cyclophosphamide 59Pemetrexed 55Bevacizumab 54durvalumab 53Doxorubicin 52Radiotherapy 49Capecitabine 49Radiation 47Oxaliplatin 47Fluorouracil 47Rituximab 42Leucovorin 42Vincristine 41Lenalidomide 40Etoposide 38Letrozole 36atezolizumab 35Nivolumab 35Prednisone 31Bortezomib 31130-nm albumin-bound paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × cabazitaxel × 90 days × Clear all
NCT07213674 2026-06-04

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Amgen

Phase 3 Recruiting
750 enrolled
Genitourinary

Prostatic Neoplasms

NCT07611110 2026-05-28

VECTRA-01

AstraZeneca

Phase 3 Recruiting
670 enrolled
Genitourinary

Prostatic Neoplasms

NCT06691984 2026-05-15

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Amgen

Phase 3 Active not recruiting
707 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT02044354 2026-04-01

CABA-DOC

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Completed
195 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡